Some people living with chronic stress have a higher risk of stroke, according to a new study. The study looked at younger adults and found an association between stress and stroke, with no known ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults. The approval was supported by data from th ...

SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox ...

A new study found that moderate stress levels were associated with a 78% increased risk of stroke in female participants, but ...

Chronic stress could be a hidden stroke risk for younger women, according to new research. Scientists found that women aged 18 to 49 who reported moderate stress levels had a significantly higher ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

Heart diseases, neoplasms and stroke were the top three causes of death in the country from January to August of 2024, according to the Philippine Statistics Authority ...

Every year, millions of people die from stroke. In order to win against this disease which occurs the moment when a blood ...

A study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...

RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.